Skip to Content

Teniposide Dosage

Medically reviewed on August 4, 2017.

Applies to the following strengths: 10 mg/mL

Usual Adult Dose for Acute Lymphocytic Leukemia

For use in the treatment of patients with refractory childhood acute lymphoblastic leukemia:

Patients failing induction therapy with a cytarabine-containing regimen:
165 mg/m² by slow IV infusion and 300 mg/m² cytarabine IV twice weekly for 8 to 9 doses.

Patients refractory to vincristine/prednisone-containing regimens:
250 mg/m² by slow IV infusion and 1.5 mg/m² vincristine IV weekly for 4 to 8 weeks with 40 mg/m² prednisone orally for 28 days.

Usual Adult Dose for non-Hodgkin's Lymphoma

30 mg/m2/day for 10 days

or

50 to 100 mg/m2 once a week as a single agent

or

60 to 70 mg/m2/day once a week in combination with other chemotherapeutic agents

Usual Pediatric Dose for Acute Lymphoblastic Leukemia

In combination with other approved anticancer agents, teniposide is indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia in the following regimens:

Patients failing induction therapy with a cytarabine-containing regimen:
165 mg/m² by slow IV infusion and 300 mg/m² cytarabine IV twice weekly for 8 to 9 doses.

or

Patients refractory to vincristine/prednisone-containing regimens:
250 mg/m² by slow IV infusion and 1.5 mg/m² vincristine IV weekly for 4 to 8 weeks with 40 mg/m² prednisone orally for 28 days.

or

165 mg/m2 by slow IV infusion on days 1 and 2 of weeks 3, 13, and 23

Renal Dose Adjustments

There is insufficient data and there are no specific dose adjustment recommendations. However, dose adjustments may be necessary.

Liver Dose Adjustments

There is insufficient data and there are no specific dose adjustment recommendations. However, dose adjustments may be necessary.

Dose Adjustments

Patients with Down syndrome and leukemia may be more sensitive to the myelosuppressive effects. Therefore, the first course should be administered at half the usual dose and the dose should be adjusted in subsequent cycles upward based on degree of toxicities (myelosuppression and mucositis) in the previous course(s).

Precautions

US BOXED WARNINGS:
-This drug should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents in facilities equipped to manage therapy and treat complications.
-Severe myelosuppression with resulting infection or bleeding may occur.
-Hypersensitivity reactions, including anaphylaxis-like symptoms, may occur with initial dosing or at repeated exposure to this drug. Epinephrine (with or without corticosteroids and antihistamines) has been used to alleviate symptoms of hypersensitivity.

Consult WARNINGS section for additional precautions.

Dialysis

There is insufficient data and there are no specific dose adjustment recommendations. However, dose adjustments may be necessary.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide